Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy

被引：18

作者：

Nghiem, Paul

Bhatia, Shailender

Brohl, Andrew Scott

Hamid, Omid

Mehnert, Janice M.

Terheyden, Patrick

Shih, Kent C.

Brownell, Isaac

Lebbe, Celeste

Lewis, Karl D.

Linette, Gerald P.

Milella, Michele

Hennessy, Meliessa

Bajars, Marcis

Hicking, Christine

D'Angelo, Sandra P.

机构：

[1] Univ Washington, Med Ctr, South Lake Union, Seattle, WA 98195 USA

[2] Univ Washington, Med Ctr, Seattle, WA 98195 USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[4] Angeles Clin & Res Inst, Los Angeles, CA USA

[5] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[6] Univ Lubeck, Dept Dermatol, Lubeck, Germany

[7] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA

[8] NCI, Bethesda, MD 20892 USA

[9] Univ Paris Diderot, CIC Dept, AP HP, Paris, France

[10] Univ Paris Diderot, Dept Dermatol, AP HP, Paris, France

[11] Univ Colorado Denver, Sch Med, Aurora, CO USA

[12] Univ Penn, Sch Med, Philadelphia, PA 19104 USA

[13] IRCCS, Ist Nazl Tumori Regina Elena, Rome, Italy

[14] EMD Serono Inc, Billerica, MA USA

[15] Merck KGaA, Darmstadt, Germany

[16] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[17] Weill Cornell Med Coll, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.9507

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9507

引用

页数：2

共 42 条

[31] Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): Pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study.
Apolo, Andrea B.
Ellerton, John Allan
Infante, Jeffrey R.
Agrawal, Manish
Gordon, Michael S.
Aljumaily, Raid
Britten, Carolyn D.
Dirix, Luc Yves
Lee, Keun-Wook
Taylor, Matthew H.
Schoffski, Patrick
Wang, Ding
Ravaud, Alain
Gelb, Arnold
Xiong, Junyuan
Rosen, Galit
Patel, Manish R.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[32] Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
Apolo, Andrea B.
Ellerton, John A.
Infante, Jeffrey R.
Agrawal, Manish
Gordon, Michael S.
Aljumaily, Raid
Gourdin, Theodore
Dirix, Luc
Lee, Keun-Wook
Taylor, Matthew H.
Schoeffski, Patrick
Wang, Ding
Ravaud, Alain
Manitz, Juliane
Pennock, Gregory
Ruisi, Mary
Gulley, James L.
Patel, Manish R.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
[33] A phase II, open-label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel cell carcinoma progressing on anti-PD-(L)1 antibody therapy: The MERKLIN 2 study.
Van Akkooi, Alexander Christopher Jonathan
Ascierto, Paolo Antonio
Nathan, Paul D.
Nghiem, Paul
Reimann, Philip
Hermann, Frank
Becker, Jurgen C.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[34] Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study
Tsimafeyeu, Ilya
Chubenko, Vyacheslav
Baklanova, Olga
Kalpinskiy, Alexey
Safina, Sufia
Lebedinets, Andrei
Petkau, Vladislav
Parsadanova, Elvira
Turganova, Maria
Shkurat, Aleksei
Tovbik, Natalia
Tkacheva, Elena
Anzhiganova, Yulia
Novikova, Olga
Bragina, Varvara
Zukov, Ruslan
Orlova, Rashida
CURRENT ONCOLOGY, 2025, 32 (01)
[35] Open-label Phase-II-Study for Evaluating the Efficacy and Safety of Domatinostat in Combination with Avelumab in advanced, unresectable/metastatic Merkel Cell Carcinoma Patients with Progression under Anti-PD-(L) 1-Antibody Therapy - The MERKLIN 2 Study
Terheyden, P.
Van Akkooi, A.
Ascierto, P. A.
Nghiem, P.
Henneberg, J.
Hermann, F.
Becker, J. C.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 26 - 26
[36] Two-year outcomes of clinical N2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study
Yang, Yang
Liu, Jun
Liu, Zhichao
Zhu, Li
Chen, Hezhong
Yu, Bentong
Zhang, Renquan
Shao, Jinchen
Zhang, Ming
Li, Chunguang
Li, Zhigang
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2024, 167 (03):
[37] Discussion to: Two-year outcomes of clinical N2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study
Li, Zhigang
Ferri, Lorenzo
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2024, 167 (03): : 848 - 848
[38] Three-Year Efficacy and Safety Update From the Phase III Checkmate 025 Study of Nivolumab (NIVO) v Everolimus (EVE) in Patients With Advanced Renal Cell Carcinoma (aRCC)
Sharma, P.
Tykodi, S. S.
Escudier, B.
Carducci, M.
Oudard, S.
Hammers, H. J.
George, S.
Gauna, D. C.
Alva, A. S.
Richardet, M. E.
Chevreau, C.
Plimack, E. R.
Srinivas, S.
Procopio, G.
Sosman, J. A.
McDermott, D.
Choueiri, T. K.
Gauler, T.
Berghorn, E.
Yang, L.
Motzer, R.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 78 - 78
[39] Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups
Ferris, R. L.
Blumenschein, G. R.
Fayette, J.
Guigay, J.
Colevas, A. D.
Licitra, L.
Harrington, K.
Kasper, S.
Vokes, E. E.
Even, C.
Worden, F.
Saba, N. F.
Docampo, LCIglesias
Haddad, R. I.
Rordorf, T.
Kiyota, N.
Tahara, M.
Lynch, M.
Li, L.
Gillison, M.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (05): : 1317 - 1317
[40] Phase II, multicenter, randomized, open-label, parallel-arm, umbrella study JAVELIN Bladder Medley of avelumab (MSB0010718C) in combination with sacituzumab govitecan, M6223 and NKTR-255 as maintenance therapy in participants with locally advanced or metastatic urothelial carcinoma treated with first-line platinum-containing therapy (1L) chemotherapy has not progressed. - JAVELIN Bladder Medley - AB 88/23 from AUO
Rexer, Heidrun
Banek, Severine
Merseburger, Axel S.
AKTUELLE UROLOGIE, 2023, 54 (06) : 438 - 440

← 1 2 3 4 5 →